Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: Outcome and clinical implications

S. Viviani, E. Camerini, V. Bonfante, A. Santoro, M. Balzarotti, M. Fornier, L. Devizzi, P. Verderio, P. Valagussa, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 sIL-2R serum levels were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-up. Baseline sIL-2R levels (mean ± standard error) were significantly higher in patients than in 65 healthy control subjects (1842 ± 129 U ml-1 vs 420 ± 10 U ml-1, P <0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean sIL-2R serum levels were significantly lower than those at diagnosis (635 ± 19 U ml-1 vs 1795 ± 122 U ml-1, P= 0.0001). After a median follow-up of 5 years, sIL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed. However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression was linearly related to sIL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of sIL-2R compared with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic factors, such as number of involved sites, presence of B symptoms and extranodal extent.

Original languageEnglish
Pages (from-to)992-997
Number of pages6
JournalBritish Journal of Cancer
Volume77
Issue number6
Publication statusPublished - 1998

    Fingerprint

Keywords

  • Hodgkin's disease
  • Prognostic factor
  • Soluble interleukin 2 receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this